# US 7,713,525 B2 · Biomarkers for cancer sensitivity and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,713,525 B2
- Document ID: US7713525B2
- Status: Granted
- Kind: B2
- Application number: 11/877,234
- Filed: 2007-10-23
- Published: 2008-04-24
- Granted: 2010-05-11
- Earliest claimed: 2006-10-23
- Assignees: The UAB Research Foundation
- Inventors: Robert P. Kimberly; Tong Zhou; Takeshi Isoyama
- Web page: https://patentgrep.com/patent/US7713525B2

## CPC

- G01N 33/5011: {for testing antineoplastic activity}
- A61P 35/00: Antineoplastic agents
- G01N 33/5088: {of vertebrates}
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 2333/4703: Regulators; Modulating activity
- G01N 2333/908: acting on hydrogen peroxide as acceptor (1.11)
- G01N 2333/91225: with a carboxyl group as acceptor (2.7.2)
- G01N 2333/988: Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are biomarkers and uses thereof for evaluating anti-cancer efficacy and sensitivity.

## Claims

### Claim 1

A method of predicting or monitoring the efficacy an anti-cancer agent in a subject with cancer comprising:
(a) administering the agent to the subject with cancer, wherein the agent is TRA-8 or an antibody having the same epitope specificity as TRA-8;
(b) acquiring a biological sample from the subject; and
(c) detecting levels of PGK1, an increase in levels compared to baseline levels indicating efficacy.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody having the same epitope specificity as TRA-8 is a humanized version of TRA-8.